416 related articles for article (PubMed ID: 33248510)
41. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
42. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries.
Obeng-Kusi M; Habila MA; Roe DJ; Erstad B; Abraham I
J Med Econ; 2021 Nov; 24(sup1):1-13. PubMed ID: 34866541
[TBL] [Abstract][Full Text] [Related]
43. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Kondili LA; Blach S; Razavi H; Craxì A
Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
[TBL] [Abstract][Full Text] [Related]
44. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
45. Cost-effective options for the prevention and management of gastrointestinal and liver disease in the Asia-Pacific region.
Roberts-Thomson IC; Lung T
J Gastroenterol Hepatol; 2018 Jan; 33(1):121-127. PubMed ID: 28833619
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.
Stevens ER; Nucifora KA; Hagan H; Jordan AE; Uyei J; Khan B; Dombrowski K; des Jarlais D; Braithwaite RS
Clin Infect Dis; 2020 Jun; 70(12):2652-2662. PubMed ID: 31400755
[TBL] [Abstract][Full Text] [Related]
47. Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control.
Cirera L; Galatas B; Alonso S; Paaijmans K; Mamuquele M; Martí-Soler H; Guinovart C; Munguambe H; Luis F; Nhantumbo H; Montañà J; Bassat Q; Candrinho B; Rabinovich R; Macete E; Aide P; Alonso P; Saúte F; Sicuri E
PLoS One; 2020; 15(7):e0235631. PubMed ID: 32628741
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
Scott N; Palmer A; Morgan C; Lesi O; Spearman CW; Sonderup M; Hellard M
Lancet Glob Health; 2018 Jun; 6(6):e659-e667. PubMed ID: 29773122
[TBL] [Abstract][Full Text] [Related]
49. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
[No Abstract] [Full Text] [Related]
50. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
51. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
52. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
Easterbrook P; Sands A; Harmanci H
Semin Liver Dis; 2012 May; 32(2):147-57. PubMed ID: 22760654
[TBL] [Abstract][Full Text] [Related]
53. Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries.
Nayagam S; Sicuri E; Lemoine M; Easterbrook P; Conteh L; Hallett TB; Thursz M
BMC Infect Dis; 2017 Nov; 17(Suppl 1):692. PubMed ID: 29143675
[TBL] [Abstract][Full Text] [Related]
54. Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China.
Liu Y; Zhang H; Zhang L; Zou X; Ling L
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012839
[TBL] [Abstract][Full Text] [Related]
55. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
Custer B; Janssen MP; Hubben G; Vermeulen M; van Hulst M
Vox Sang; 2017 Aug; 112(6):526-534. PubMed ID: 28597489
[TBL] [Abstract][Full Text] [Related]
56. Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator.
Adee M; Zhuo Y; Zhong H; Zhan T; Aggarwal R; Shilton S; Chhatwal J
Sci Rep; 2021 Nov; 11(1):21382. PubMed ID: 34725356
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis C virus elimination in Indonesia: Epidemiological, cost and cost-effectiveness modelling to advance advocacy and strategic planning.
Trickey A; Hiebert L; Perfect C; Thomas C; El Kaim JL; Vickerman P; Schȕtte C; Hecht R
Liver Int; 2020 Feb; 40(2):286-297. PubMed ID: 31454466
[TBL] [Abstract][Full Text] [Related]
58. Impact and Cost-Effectiveness of Biomedical Interventions on Adult Hepatitis B Elimination in China: A Mathematical Modelling Study.
Wang X; Du Z; Wang Y; Wang J; Huang S; Wang Y; Gu J; Deng W; Gilmour S; Li J; Hao Y
J Epidemiol Glob Health; 2023 Sep; 13(3):517-527. PubMed ID: 37349664
[TBL] [Abstract][Full Text] [Related]
59. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries.
Wright CM; Boudarène L; Ha NT; Wu O; Hawkins N
BMC Public Health; 2018 Mar; 18(1):373. PubMed ID: 29558894
[TBL] [Abstract][Full Text] [Related]
60. Cost-Effectiveness of Hepatitis C Screening and Treatment in Low-Income, Primarily Hispanic Baby Boomers.
Hollenbeak CS; Rochat A; Hollenbeak AC; Choi AN; Gutierrez J; Turner BJ
J Health Care Poor Underserved; 2019; 30(3):1053-1067. PubMed ID: 31422988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
